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Relapse in patients with schizophrenia has devastating repercussions, including worsening symptoms, impaired
functioning, cognitive deterioration and reduced quality of life. This progressive decline exacerbates the burden of
illness on patients and their families. Relapse prevention is identified as a key therapeutic aim; however, the
absence of widely accepted relapse definition criteria considerably hampers achieving this goal. We conducted a
literature review in order to investigate the reporting of relapses and the validity of hospitalization as a proxy for
relapse in patients with schizophrenia. The primary aim was to assess the range and validity of methods used to
define relapse in observational or naturalistic settings. The secondary aim was to capture information on factors
that predicted or influenced the risk of relapse. A structured search of the PubMed database identified articles that
discussed relapse, and hospitalization as a proxy of relapse, in patients with schizophrenia. National and
international guidelines were also reviewed. Of the 150 publications and guidelines identified, 87 defined relapse
and 62% of these discussed hospitalization. Where hospitalization was discussed, this was as a proxy for, or a
component of, relapse in the majority of cases. However, hospitalization duration and type varied and were not
always well defined. Scales were used to define relapse in 53 instances; 10 different scales were used and multiple
scales often appeared within the same definition. There were 95 references to factors that may drive relapse,
including non-adherence to antipsychotic medication (21/95), stress/depression (11/95) and substance abuse (9/95).
Twenty-five publications discussed the potential of antipsychotic therapy to reduce relapse rates—continuous
antipsychotic therapy was associated with reduced frequency and duration of hospitalization. Non-pharmacological
interventions, such as psychoeducation and cognitive behavioural therapy, were also commonly reported as factors
that may reduce relapse. In conclusion, this review identified numerous factors used to define relapse.
Hospitalization was the factor most frequently used and represents a useful proxy for relapse when reporting in a
naturalistic setting. Several factors were reported to increase the risk of relapse, and observation of these may aid
the identification of at-risk patients.
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Schizophrenia is a highly prevalent disorder affecting ap-
proximately 1% of the world's population [1]. Patients
with schizophrenia often require antipsychotic medica-
tion throughout their lifetime. With correct manage-
ment, many patients can achieve symptomatic remission
[2] as defined, for example, by the Andreasen remission
criteria [3]. However, relapses are a highly prevalent
component of the disease course [4,5]. Schizophrenia is* Correspondence: jose.manuel.olivares@gmail.com
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reproduction in any medium, provided the ora significant burden, for both patients and families. The
clinical deterioration associated with each subsequent
relapse only serves to exacerbate this. For patients, re-
lapse can have devastating repercussions such as wor-
sening of symptoms, progressive cognitive deterioration,
impaired functioning and reduced quality of life [6-9].
Furthermore, families are affected by the emotional
stress and financial burden of living with and caring
for a patient with schizophrenia [10,11]. To minimize
the burden on the patient and family, it is vital that
periods of effective symptom control are extended for
as long as possible.l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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a key therapeutic aim [4-6]; however, there are currently
no established criteria by which to define relapse, and
our current understanding of relapse may not be suffi-
cient to combat this problem effectively [6,7,12,13].
We conducted a structured literature search to in-
vestigate the reporting of relapse and the validity of
hospitalization as a proxy for relapse in patients with
schizophrenia. Additionally, the factors that may be
used to predict a relapse and those factors associated
with increased or decreased risk of relapse were also
investigated.
Methods
PubMed search and literature review
A structured search of the National Center for Bio-
technology Information (NCBI) PubMed database was
performed to identify articles published from 1 January
2000 to 1 May 2010 that discussed relapse, and hospi-
talization as a proxy for relapse, in patients with schizo-
phrenia. The search term ‘Schizophrenia [Title/Abstract]
AND ((Relapse[Title/Abstract]) OR (Hospitalization
[Title/Abstract]))’ and limits (Humans, Clinical Trial,
Meta-Analysis, Review, Classical Article, Clinical Trial,
Phase IV, Comparative Study, Congresses, Controlled
Clinical Trial, Corrected and Republished Article,
Evaluation Studies, Government Publications, Journal
Article, Multicenter Study, Published Erratum, English,
French, German, Italian, Spanish) were used to identify
relevant literature from the database. The latest national
(France, Spain, Germany, Italy and the UK) and inter-
national (World Federation of Societies of Biological
Psychiatry (WFSBP); American Psychiatric Association
(APA)) guidelines were also reviewed. The primary
objective of this literature search was to determine
whether specific criteria have been used to define re-
lapse in observational and naturalistic settings. The
secondary aim was to identify possible factors that
may drive or reduce relapse.
Randomized clinical trials (RCTs) represent highly
controlled situations in which patients are required to
meet stringent inclusion criteria. Furthermore, subjects
are frequently randomized to a fixed medication dose,
without provision for dose optimization to meet individ-
ual requirements, which may likely have an impact on
patient outcomes. Patients are closely monitored in
RCTs, and specific relapse definitions are imposed for
consistency across study centres. Hence, RCTs are less
informative in regard to routine definitions of relapse
used in clinical practice and to factors associated with
relapse in unselected clinical populations. Therefore,
data from primary publications of randomized, placebo-
controlled clinical trials of pharmacological agents were
excluded from this literature search.Abstract review
Identified abstracts were excluded if they were not rele-
vant to one of the four domains:
1. Definition of relapse.
2. Factors that may predict, drive or reduce relapse.
3. Duration and frequency of relapse.
4. Cost and resource use associated with relapse.
Guidelines were reviewed using the same criteria as
the abstracts identified in the PubMed search. Following
this review, the selection of literature included 206 ab-
stracts and five guidelines.
Publications discussing the definition of relapse and
factors that may predict, drive or reduce relapse are
reviewed here. Those discussing the duration and fre-
quency of relapse or associated cost and resource are
reviewed elsewhere.
Full article review
Following abstract review, each corresponding full article
was reviewed and excluded if not relevant to one of the
four domains above. Following this review stage, the se-
lection of literature included 156 journal papers and five
guidelines. A final review of the literature was conduc-
ted. During this final review, the authors excluded those
papers describing cost-effectiveness modelling studies
that constituted secondary research as accurate inter-
pretation and evaluation of such papers require an in-
depth analysis of the methodologies and assumptions
used, which was deemed to be beyond the scope of the
current review.
The final literature selection included 145 journal
manuscripts and five guidelines from three organisations
(APA [6,14], National Institute for Clinical Excellence




Of the final selection of literature, 87 manuscripts in-
cluded a definition of relapse. None of the identified
guidelines defined relapse. Figure 2 describes the factors
used alone or in combination to define relapse. Hospi-
talization was the most widely used factor as a proxy for
relapse or as a component of the definition.
Hospitalization
‘Hospitalization’ appeared in 54% (47/87) of the publica-
tions that defined relapse, 62% (54/87) if grouped with
‘exacerbation of symptoms leading to hospitalization’. In
these 54 publications, hospitalization or exacerbation of
symptoms leading to hospitalization was discussed in 56
























Figure 1 Literature search process. The asterisk denotes that the final review process is described in detail in the main body of the text.
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as a component of a relapse definition. In the remainder
(45%, 25/56), hospitalization was discussed indepen-
dently or without reference to relapse (Table 1). The
majority of publications did not define the length of the
hospitalization or the type of hospitalization—generic
terms of ‘hospitalization’ and ‘psychiatric hospitali-
zation’ were predominantly used. Two publications,
published by the same authors, defined hospitalization
as ‘36 h of full hospitalization or a 5-day partial hos-
pitalization due to an exacerbation of acute psychotic
symptoms’. However, the difference between ‘partial’
and ‘full’ hospitalization was not defined in these publi-
cations [15,16].
Scales
There were 53 instances of a scale being used to define
relapse; however, multiple scales often appeared within
the same definition. Ten different scales were used
to define relapse (Figure 2), including the Positive
and Negative Syndrome Scale (PANSS), Clinical Global
Impression (CGI) scale (including the CGI-Severity,
CGI-Schizophrenia and CGI-Change subscales), Brief
Psychiatric Rating Scale (BPRS) and Global Assessment
of Functioning (GAF) scale, the most frequently cited
being PANSS and CGI. Generally, the scales used to de-
fine relapse assessed symptom severity and in particular
the positive symptoms of schizophrenia.
There was considerable variation between studies in
the use of each scale, in terms of the thresholds applied,and subscales used within the relapse criteria. Among
the 18 instances of using the PANSS to define relapse,
thresholds included an overall increase in the scale
[7,60,61], an increase in the score from baseline [17,18]
and recording of a score >4 for certain individual PANSS
items [62-64]. There was wide variation between studies
when using the CGI scale, since many different subscales
and thresholds were proposed to define relapse. CGI-
Severity (CGI-S) was the most commonly cited subscale,
with CGI-schizophrenia (CGI-SCH) and CGI-Change
(CGI-C) also frequently used. However, the threshold for
relapse was broadly similar regardless of the CGI sub-
scale used—with an overall increase (or increase in a sin-
gle factor) to a score of 6 or 7 being the most frequent
measure [18,19,60,65,66].Other definitions
Sixteen per cent (14/87) of publications defined relapse
as a change in behavioural patterns towards more vio-
lent or self-destructive ideation or tendencies. Exacer-
bation or re-emergence of symptoms was the fourth
most common component of definitions identified in
the literature search, second if combined with those
exacerbations that led to hospitalization.Factors that may increase or decrease the risk of relapse
Ninety-four journal articles and five guidelines discussed
the various factors that may drive or reduce relapse rates
in patients with schizophrenia.
Figure 2 Reported components of the definition for relapse. Hospitalization [11,15-59]; Positive and Negative Syndrome Scale (PANSS)
[7,15,17,18,60-72]; Clinical Global Impression (CGI) scale [17,18,26,30,52,57,60-62,65,66,68,71,73,74]; exacerbation/re-emergence of symptoms
[7,27,29,34,38,43,63,67,75-81]; deliberate self-harm or violent behaviour, suicidal or homicidal ideation, arrest [18,23,27,43,49,50,57,65,66,71,74,82-84];
Brief Psychiatric Rating Scale (BPRS) [28,43,71,76,84-91]; change of medication or patient management [18,27,38,41,56,66,75,92]; exacerbation/
re-emergence of symptoms leading to hospitalization [20,66,92-96]; clinical assessment of patient notes [38,57,88]; International Classification of
Diseases (ICD) criteria [70,89,97]; Global Assessment of Functioning (GAF) [64,72]; physician interview and/or assessment [86,98]; Present State
Examination (PSE) [84]; Global Assessment Scale (GAS) [84]; Target Symptoms Ratings Scale (TSRS) [76]; Psychiatric Assessment Scale (PAS) [99];
scale for the assessment of positive symptoms [86]; social functioning [75]; Social and Occupational Functioning Assessment Scale (SOFAS) [60].
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There were 95 references to factors that may drive re-
lapse (Figure 3), with non-adherence to antipsychotic
medication the most frequently reported factor. For ex-
ample, in a study of first-episode patients, medication
non-adherence was observed in 70% of patients with re-
lapse, compared with only 25% of those without relapse,
at 1-year follow-up (χ2 = 11.2, p = 0.001) [85]. Further-
more, in patients with recently diagnosed (≤ 2 years)
schizophrenia, a 69% relapse rate was observed in pa-
tients non-adherent to oral or depot antipsychotic ther-
apy compared with a rate of 18% in adherent patients
(χ2 = 12.66, p < 0.001) [20].Patient-specific, lifestyle and disease-related factors
associated with increased rates of relapse were also iden-
tified in the search (Figure 3). Stress/depression and
substance abuse were the second and third most fre-
quently reported factors associated with relapse. In a
retrospective cohort study, depression (adjusted hazard
ratio (AHR) = 1.44; 95% CI = 1.05, 1.98; p < 0.05) and
substance abuse (AHR = 1.80; 95% CI = 1.32, 2.47;
p < 0.05) were significantly associated with an increased
risk of psychiatric hospitalizations [97].
There were 46 instances where treatment-related fac-
tors, such as side effects, dosing issues, efficacy and gen-
eric antipsychotic use, were associated with increased
Table 1 Manuscripts that defined relapse and also discussed hospitalization used a range of definitions
Way in which hospitalization is used





Hospitalization is discussed, separately
to relapse
25 Bechdolf et al. [16]; Crown et al. [59]; dos Reis et al. [47]; Dyck et al. [32]; Hayhurst et al.
[33]; Miettunen et al. [40]; Olivares et al. [56]; Svarstad et al. [31]; Sun et al. [45];
Rabinowitz et al. [30]; Taylor et al. [22]; Thompson et al. [36]; Usall et al. [37]; Ward et al.
[25]; Weiden et al. [26]; Whitehorn et al. [39]; Janicak et al. [48]; Zhu et al. [50]; Bechdolf
et al. [15]; Drake et al. [20]; Novák-Grubic and Tacvar [34]; Olivares et al. [23]; Valencia
et al. [46]; Kim [54]; Peuskens et al. [24]
Hospitalization equates to relapse 10 Buckley et al. [44]; de Sena et al. [35]; Hawley et al. [58]; Leucht et al. [30]; Malik et al.
[11]; Rouillon et al. [49]; Spaniel et al. [52]; Spaniel et al. [53]; Taylor et al. [22];
Turkington et al. [42]
Hospitalization used as a component
of relapse definition
14 Almond et al. [38]; Ascher-Svanum et al. [57]; Csernansky et al. [17]; Drake et al. [20];
Emsley et al. [18]; Gaertner et al. [28]; Gasquet et al. [55]; Haro et al. [21]; Haro et al. [51];
Hickling et al. [29]; Hong et al. [19]; Muirhead et al. [41]; Pharoah et al. [27]; Xiang et al. [43]
Exacerbation of symptoms leading
to hospitalization equates to relapse
7 Berglund et al. [95]; Chabannes et al. [96]; Drake et al. [20]; Lancon et al. [93]; Simpson
et al. [66]; Tomaras et al. [92]; Wahlbeck et al. [94]
Figure 3 Potential drivers of relapse. Adherence problems
[2,6,7,13,17,25,26,31,34,45,47,53,57,76,85,100-105]; stress, depression,
depressive symptoms, neurosis [2,6,7,12,55,59,70,97,106-108];
substance abuse [2,6,7,21,31,57,59,83,97]; lifestyle factors
[7,12,21,38,79,109,110]; hospitalization or relapse history
[21,31,38,40,57,59,97]; treatment-related issues [6,7,28,43,61,70,111];
treatment interruption or delay [2,6,12,75,85,112,113]; disease-related
factors [57,70,83,85,97,114]; quetiapine, anticholinergics, mood
stabilizers (MS), oral neuroleptics, anxiolytics or hypnotics [21,31,51,55];
male gender [30,37,83,115]; use of first-generation antipsychotics (FGA)
vs second-generation antipsychotics (SGA) [30,85,116]; outpatient vs
inpatient [29,39]; poor patient insight [20,83]; younger age [57,83];
generic vs branded medication [117]; reduced compliance/family
involvement in Information Technology Aided Relapse Prevention in
Schizophrenia (ITAREPS) programme [53]; depot antipsychotics [76].
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interruptions to treatment due to loss of medical insur-
ance coverage were also identified. In one study, a longer
duration of untreated psychosis was significantly asso-
ciated with mild relapse in the first year after hospitali-
zation (Kruskal-Wallis test χ2 = 5.31, p = 0.02). In this
study, a mild relapse was defined as a recurrence or ex-
acerbation of psychotic symptoms in 1 week for which
an increase in antipsychotic medication was required,
without a significant decline in social functioning [75]. A
regression model analysis in another study indicated that
patients who were subject to interruptions in Medicaid
coverage were more likely to be hospitalized (negative
binomial regression z = 6.9, p < 0.001), experience a
greater number of hospitalizations (negative binomial
regression z = 8.4, p < 0.001) and spend 61% more
days in the hospital compared with patients with con-
tinuous coverage (exponential regression model z = 7.1,
p < 0.001) [112].
Factors that may reduce the rate of relapse
There were 49 occurrences (in 46 publications) of fac-
tors that may reduce the rate of relapse (Figure 4). The
potential for antipsychotic therapy to reduce relapse
rates was examined in a total of 25 publications. One
publication reported the results from a 3-year follow-up
of a large cohort of outpatients with schizophrenia ta-
king part in the prospective, observational European
Schizophrenia Outpatient Health Outcomes (SOHO)
study (n = 6516) [21]. In this study, relapse rates were
higher in patients who took typical antipsychotics (depot
(relative risk (RR) = 1.689; 95% CI = 1.306, 2.184;
p < 0.0001) or oral (RR = 1.655; 95% CI = 1.316, 2.081;
p < 0.0001)) than the atypical antipsychotic olanzapine.
Differences in the RR for relapse were also observed bet-
ween olanzapine and other second-generation antipsy-
chotics (SGAs) [21].
Figure 4 Factors that may reduce relapse rates. Individual
citations of each factor: a single reference may include citations
of more than one factor. The antipsychotic medication category
does not include the other pharmacological therapy factors. Non-
pharmacological therapies [4-6,11,14-16,27,32,41,42,64,82,84,92,118-121];
antipsychotic medication [4,6,23,54,81,122-127]; risperidone/risperidone
long-acting injectable (RLAI) specifically [22-24,35,65,74,128-131];
medication compliance [25,33,132,133]; Information Technology Aided
Relapse Prevention in Schizophrenia (ITAREPS) [52]; good patient
insight [134]; early detection [135]; greater frequency of
electroconvulsive therapy (ECT) [90]; olanzapine specifically [21].
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with depot antipsychotics had a higher rate of major re-
lapses and hospitalization compared with patients who
had not received depot antipsychotics [76]. However,
this study primarily examined the outcome of therapy in
relation to medication adherence and defined a ‘depot
patient’ as one who had received a depot antipsychotic
‘at any time during the study’, which included patients
who started therapy with an oral antipsychotic but were
later switched to a depot antipsychotic due to poor
adherence. Therefore, the extent to which adherence
problems caused both the switch to depot antipsychotic
therapy and the relapse in these ‘depot patients’ is un-
clear. Moreover, it was not reported whether relapse oc-
curred prior to, or following, initiation of treatment with
the depot antipsychotic [76].
The effect of risperidone long-acting injectable (RLAI)
on relapse rates and duration of hospitalization or re-
lapse compared with baseline [22,128] or compared with
patients treated with oral antipsychotics was reported in
several publications [18,23]. In one post hoc analysis of
two similarly designed 2-year studies (one RLAI and one
oral antipsychotic study), RLAI administration was asso-
ciated with a relapse rate of 9.3% compared with 42.1%
in patients treated with oral antipsychotics (p = 0.001)
[18]. In a study comparing hospitalization at 1 and 2
years after RLAI initiation, greater decreases from base-
line in the number of patients hospitalized and the
number and length of hospital stays in patients whocontinued with RLAI treatment were observed, com-
pared with those who discontinued [24].
Non-pharmacological interventions, such as psychoedu-
cation and cognitive behavioural therapy (CBT), were also
commonly reported as factors that may reduce relapse.
However, these interventions were evaluated in patients
already receiving treatment with antipsychotic medication
[4]. Many publications highlighted a ‘trend’ associating
therapies such as CBT and psychoeducation with
relapse reduction but failed to demonstrate statisti-
cally significant effects in observational or naturalis-
tic settings.
Discussion
The consistent and correct assessment and management
of relapse in patients with schizophrenia are vital for
clinical practice and important factors for controlled
clinical trials. As such, an awareness of the factors that
may be associated with increased and decreased rates of
relapse should invariably aid clinical practice and benefit
patients. However, reporting physicians do not always
state how they define relapse; only 62% (87/145) of the
final selection of journal articles identified in this litera-
ture search stated a definition of relapse. Interestingly,
none of the international and national guidelines define
relapse, potentially indicating that in clinical practice, a
psychiatrist is deemed able to identify a relapsing pa-
tient. Alternatively, acutely exacerbated patients may
present with a range of signs and symptoms to such a
variable degree as to hinder the provision of a unique re-
liable definition of relapse.
Csernansky and colleagues [17] proposed a set of
multifactorial criteria for defining relapse, including hos-
pitalization, and suggested that any single factor could
be used as a clinical determinant of relapse. Within the
studies identified in this search, many factors were used
to define relapse. Hospitalization, usually defined in ge-
neric terms of ‘hospitalization’ or ‘psychiatric hospita-
lization’, was the single factor most commonly used to
define relapse and represents a commonly used proxy
for examining relapse; however, hospitalization was also
one of the search terms used and so may bias the results.
In particular, the majority of the retrospective database
analyses identified in this literature search specifically in-
vestigated hospitalization when conducting their ana-
lyses, rather than relapse or other parameters that could
potentially be used to define relapse (that may not have
been available in the original data source). It is also likely
that hospitalization is frequently used to define relapse
since it is simple to measure and provides tangible data
to analyse. However, schizophrenia is a heterogeneous
condition in which a patient might relapse (moderate
symptom exacerbation) and not be hospitalized or con-
versely might be hospitalized for other reasons, such as
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chiatric symptoms.
Clinical scales and criteria were also frequently identi-
fied in the literature and provide a clinically validated
and standardized method of assessment. In clinical stud-
ies, where symptoms are measured at baseline and then
at set intervals, scales are ideal to characterize patients;
however, they can be time-consuming and require add-
itional training to perform since most of them are not
intuitive, and are therefore often inconvenient for use in
routine clinical practice. Behavioural changes and clinical
assessments were least frequently used to define relapse in
patients with schizophrenia and were poorly defined in
the literature, but are likely to be used in everyday clinical
practice. The low frequency of use in clinical studies prob-
ably reflects that physician variability may be a significant
factor in behavioural and clinical definitions.
Factors that were associated with an increased or de-
creased risk of relapse included adherence to medication,
stress, psychosocial therapies, previous hospitalization/re-
lapse and patient insight. The most prominent factor re-
lated to increased risk of relapse was partial/non-adherence
to antipsychotic medication [25,76,85]. Indeed, it is well
established that treatment with antipsychotic medication
can offer an effective option for relapse prevention as well
as other beneficial patient outcomes. For instance, in an
analysis of a nationwide cohort of 2,588 consecutive
patients hospitalized for the first time with a diagnosis of
schizophrenia in Finland, 1,496 patients (57.8%) were
rehospitalized due to relapse during a mean follow-up
period of 2 years; use of any antipsychotic was associated
with a lower risk of rehospitalization compared with
no use of antipsychotics (Cox model hazard ratio = 0.38,
95% CI = 0.34–0.43; marginal structural model hazard
ratio = 0.48, 95% CI = 0.42–0.56) [136].
Increasing gaps in medication intake over 1 year can
result in a greater risk of hospitalization (up to a four-
fold increase) [26]. The use of continuous medication,
through increased adherence to antipsychotic medica-
tion or use of medications that give assured delivery,
was the most frequently identified factor associated with
reduced relapse or hospitalization rates [18,22,23,128].
These findings highlight the current focus on anti-
psychotic medication in the literature and the impor-
tance of monitoring and improving medication adherence
in patients with schizophrenia.
While primary research articles concerning RCTs were
removed from the initial results for the reasons outlined
above (see ‘Methods’), the literature search identified
one meta-analysis performed by Leucht et al. [86], cover-
ing 17 RCTs, where the heterogeneity of definitions of
relapse used mirrored those seen in naturalistic studies.
With the exception of RCTs conducted by the same
pharmaceutical company, each study used a distinctdefinition of relapse. Nevertheless, hospitalization, due
to an exacerbation of psychotic symptoms, was a key
component of most of the methods used to define
relapse. While the search was designed to capture de-
finitions of relapse as they relate to routine clinical
practice, rather than more selected clinical popula-
tions, nevertheless consideration of RCTs of antipsy-
chotic treatments is informative, particularly in terms
of their impact on relapse reduction since this is fre-
quently included as one of the study outcomes. Sys-
tematic review and meta-analysis of RCTs are often
used as a method of comparing the effects of diffe-
rent antipsychotics. One such study suggested that
SGAs may have a greater ability to prevent relapse
than first-generation antipsychotics (FGAs) [86], but
the influence of patient adherence to treatment on
this finding is uncertain, and the extent of the diffe-
rence varied between treatments [137].
A number of meta-analyses have been conducted of
relapse rates of depot/long-acting injectable (LAI) anti-
psychotics compared with oral antipsychotics based on
RCTs; however, the study conclusions are not all in
agreement. Leucht et al. [138] reported that in studies of
12 months or more comparing depot with oral antipsy-
chotics in schizophrenia, depot formulations reduced re-
lapse significantly, with a relative and absolute risk of
30% and 10%, respectively (RR = 0.70; 95% CI = 0.57,
0.87; number needed to treat (NNT) = 10; 95% CI = 6,
25; p = 0.0009). A similar superiority of depot over oral
formulations (RR = 0.31; 95% CI = 0.21–0.41 vs RR =
0.46; 95% CI = 0.37–0.57; p = 0.03) has been reported in
a meta-analysis of RCTs of antipsychotics versus placebo
for relapse prevention in schizophrenia [139]. However,
a meta-analysis published subsequently by some of the
same authors found no superiority of pooled LAIs com-
pared with oral antipsychotics in relapse prevention
(studies = 21, n = 4950, RR = 0.93; 95% CI = 0.80, 1.08;
p = 0.35) [140]. The authors speculated that publication
bias in older studies (prior to requirements for registra-
tion and publication of results of all clinical trials), chan-
ging definitions of relapse over time and increasing use
of oral SGAs as comparators may all influence the diffe-
rence in findings between older and more recent RCTs.
One interpretation of these differences in findings is that
RCTs may over-represent patients with greater adher-
ence to treatment, and with less severe illness compared
with the wider population of patients with schizophre-
nia. Consistent with this assertion, a meta-analysis of
mirror-image open studies (pre- and post-introduction
of LAI antipsychotics) within subjects showed a strong
superiority of LAI antipsychotics in preventing a next
hospitalization (16 studies, n = 4,066; RR = 0.43; 95% CI =
0.35–0.53; p < 0.001, NNT = 3) and in decreasing the
number of hospitalizations (15 studies, 6,396 person-
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[141]. This clear superiority was maintained in subgroup
analyses of FGA LAI antipsychotics, SGA LAI antipsy-
chotics, studies published before 2000, studies published
after 2000, studies reporting intention-to-treat analyses
and studies reporting observed cases, with the authors
concluding that analyses of naturalistic studies may better
represent the clinical population likely to be treated with
LAI antipsychotics in routine care.
In non-RCTs identified in the current literature review,
non-pharmacological interventions, such as psychoedu-
cation and CBT, were also commonly reported as factors
that may reduce relapse and were recommended as im-
portant components of schizophrenia management stra-
tegies by national guidelines [4].
Conclusions
In conclusion, this literature search identified numerous
factors that have been used to define relapse. Hospi-
talization was the factor most frequently used to define
relapse, and this represents a useful proxy for relapse
when reporting in a naturalistic setting. Several factors
are reported potentially to increase or decrease the risk
of relapse in patients with schizophrenia. Although reli-
able predictors for relapse have not been identified, ob-
servation of these factors may aid the identification of
at-risk patients. Continuous antipsychotic medication
appears to be one of the most prominently reported fac-
tors to reduce the risk of relapse and should be a priority
for psychiatrists.
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